Skip to main content
Log in

Proton Pump Inhibitor-Induced Neutropenia

Possible Cross-Reactivity between Omeprazole and Pantoprazole

  • Case Report
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Proton pump inhibitors (PPIs) are widely used drugs in the treatment or prophylaxis of peptic ulcer and gastro-oesophageal reflux disease. In addition to their well documented efficacy, these drugs are generally well tolerated with only rare serious adverse effects having been reported. Neutropenia and agranulocytosis are rare adverse events associated with PPI treatment. All previously published cases of isolated neutropenia have involved omeprazole, but leukopenia is labelled as a possible adverse effect in the summary of product characteristics of the other PPIs. In this report, we describe a case of omeprazole-induced neutropenia with further recurrence upon pantoprazole treatment.

A 60-year-old man with chronic alcoholism and a medical history of pulmonary tuberculosis, untreated chronic C hepatitis, peripheral artery disease, chronic obstructive pulmonary disease and stable stage 3 chronic kidney disease was admitted with dehydration and malnutrition. Omeprazole 20 mg/day and sucralfate 3 g/day were started for diffuse gastritis on gastric endoscopy. While the patient’s blood cell count had been within the normal range before this treatment, routine laboratory examination revealed moderate neutropenia (0.9 × 109/L) after 9 days of treatment. His blood cell count returned to the normal range after discontinuation of omeprazole and no further episodes of neutropenia were noted in the following months. One year later, oesophago-gastroscopy revealed a hiatal hernia with an extensive zone of Barrett’s oesophagus. As the lesions did not improve with ranitidine and sucralfate therapy, the patient was started on pantoprazole 40 mg/day. His initial white blood cell count was normal, but moderate neutropenia (0.8 × 109/L) was again noted after only 2 days of pantoprazole treatment. Complete and further stable normalization was obtained within 3 days after replacement of pantoprazole with ranitidine.

Toxic and immune-mediated mechanisms are the two commonly proposed mechanisms to explain the pathogenesis of drug-induced neutropenia. This report suggests that PPI-induced neutropenia is immune mediated and argues for a possible cross-reactivity between the two PPIs, as has already been described for PPI-induced hypersensitivity reactions. The report also indicates that patients with a history of neutropenia induced by one PPI may be at risk of recurrence of neutropenia if given another member of this drug class. In these patients, close haematological monitoring is proposed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. IMS Health Report. Global sales and prescription information, 2007 [online]. Available from URL: http://www. imshealth.com/portal/site/imshealth/menuitem [Accessed 2009 Jun 24]

  2. Holt TL, Coombes ID, Pillans PI, et al. Neutropenia associated with omeprazole. Med J Aust 1999; 170: 141–2

    PubMed  CAS  Google Scholar 

  3. Ottervanger JP, Stricker BH, Kappelle JW, et al. Omeprazole-associated agranulocytosis. Eur J Haematol 1995; 54: 279–80

    Article  PubMed  CAS  Google Scholar 

  4. Gabutti L, Stoller R, Vogt B. Omeprazole-induced agranulocytosis in a kidney transplant recipient. Nephrol Dial Transplant 1999; 14: 523–4

    Article  PubMed  CAS  Google Scholar 

  5. Losec® Capsules 10 mg, 20 mg and 40 mg: summary of product characteristics. Astra Zeneca UK. Last revision: 21 Jul 2008 [online]. Available from URL: http://www.medicines. org.uk [Accessed 2010 May 14]

  6. Pantoloc Control 20mg gastro-resistant tablets: summary of product characteristics. Nycomed UK Ltd. Last revision: 23 Mar 2010 [online]. Available from URL: http://www.medicines.org.uk [Accessed 2010 May 14]

  7. Pariet 10 mg and 20 mg: summary of product characteristics. Eisai Ltd. Last revision 28 Apr 2010 [online]. Available from URL http://www.medicines.org.uk [Accessed 2010 May 14]

  8. Nexium® 20mg and 40mg tablets: summary of product characteristics. Astra Zeneca UK. Last revision: 22 Oct 2009 [online]. Available from URL: http://www.medicines. org.uk [Accessed 2010 May 14]

  9. Lansoprazole 15mg gastro-resistant capsules: summary of product characteristics. Astra Winthrop Pharmaceuticals UK Ltd. Last revision: 30 Apr 2010 [online]. Available from URL: http://www.medicines.org.uk [Accessed 2010 May 14]

  10. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42Suppl. 3: S1–201

    Google Scholar 

  11. Tavassoli N, Duchayne E, Sadaba B, et al. Detection and incidence of drug-induced agranulocytosis in hospital: a prospective analysis from laboratory signals. Eur J Clin Pharmacol 2007; 63: 221–8

    Article  PubMed  CAS  Google Scholar 

  12. Andrès E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol 2008; 15: 15–21

    Article  PubMed  Google Scholar 

  13. Ramos-Casals M, García-Carrasco M, López-Medrano F, et al. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. Medicine (Baltimore) 2003; 82: 87–96

    Article  CAS  Google Scholar 

  14. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–45

    Article  PubMed  CAS  Google Scholar 

  15. Bhatt V, Saleem A. Review: drug-induced neutropenia. Pathophysiology, clinical features, and management. Ann Clin Lab Sci 2004; 34: 131–7

    PubMed  Google Scholar 

  16. Pisciotta AV. Drug-induced agranulocytosis: peripheral destruction of polymorphonuclear leukocytes and their marrow precursors. Blood Rev 1990; 4: 226–37

    Article  PubMed  CAS  Google Scholar 

  17. Palmblad J, Papadaki HA, Eliopoulos G. Acute and chronic neutropenias: what is new? J Intern Med 2001; 250: 476–91

    Article  PubMed  CAS  Google Scholar 

  18. Castot A, Bidault I, Dahan R, et al. Evaluation of unexpected and toxic effects of omeprazole (Mopral) reported to the regional centers of pharmacovigilance during the first 22 postmarketing months. Therapie 1993; 48: 469–74

    PubMed  CAS  Google Scholar 

  19. Lobera T, Navarro B, Del Pozo MD, et al. Nine cases of omeprazole allergy: cross-reactivity between proton pump inhibitors. J Investig Allergol Clin Immunol 2009; 19: 57–60

    PubMed  CAS  Google Scholar 

  20. Vovolis V, Koutsostathis N, Stefanaki E. IgE-mediated anaphylaxis to proton pump inhibitors-cross-reacting study. Allergy 2008; 63: 1251–2

    Article  PubMed  CAS  Google Scholar 

  21. Garrido Fernández S, Cumplido JA, Rábano A, et al. Allergy to proton pump inhibitors: diagnosis and assessment of cross-reactivity. J Investig Allergol Clin Immunol 2008; 18: 140–1

    Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this case report. The authors have no conflicts of interest that are directly relevant to the content of this report.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Aurore Gouraud.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gouraud, A., Vochelle, V., Descotes, J. et al. Proton Pump Inhibitor-Induced Neutropenia. Clin. Drug Investig. 30, 559–563 (2010). https://doi.org/10.2165/11537230-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11537230-000000000-00000

Keywords

Navigation